

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Arnold D. Kaluzny, longtime adviser to the NCI and health services researcher, dies at 87
- Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays - Natalie Phelps, whose clinical trial was delayed due to RIFs, dies of colon cancer
- Shane Jacobson talks about his to-do list for ACS
Boost research, forge closer ties with cancer centers, launch an all-out campaign for resources - My introduction to, and lessons learned from, Rick Pazdur











